Johnson & Johnson Vision's Podcast
Vision Matters, brought to you by Johnson & Johnson Vision, is a series of conversations, enabling eye care professionals to reflect on their practice and ensure they can continue to provide excellence in patient care. Eye care professionals in the UK can gain 1 CPD point by listening to an episode and completing the accompanying exercise available on www.jnjvisionpro.co.uk.
Important Safety Information
ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For complete information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use or visit our website www.jnjvisionpro.co.uk
Johnson & Johnson Vision's Podcast
Vision Matters Podcast Episode 3: Presbyopia & Beyond
This episode focuses on the advancements of multifocal IOL technology and considers possible future improvements of multifocal contact lens design. Our guest host, Dr Katherine Evans, Senior Lecturer at Cardiff University, speaks to Mr Damian Lake, Consultant Ophthalmologist, and Tom Karkkainen, Senior Principal Research Optometrist at Johnson & Johnson Vision, who share advancements in their respective fields.
PP2023OTH5653
Important Safety Information
ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For complete information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use or visit our website www.jnjvisionpro.co.uk
© Johnson & Johnson Medical Ltd 2025.